Objective To investigate the changes of CD4+,CD8+and B cells in peripheral blood of breast cancer patients detected before and after surgery and following chemotherapy and the relationship with clinical prognosis.Methods Seventy-nine pa-tients with breast cancer who were admitted for treatment in the Department of General Surgery,Shanghai Minhang Central Hospital from July 2015 to March 2017 were enrolled for the study.T cell and B cell counts were detected by flow cytometry in the peripheral blood of breast cancer patients and benign breast cancer patients,and differences were analyzed between the patients of the 2 groups.Then,the relationship between T cell and B cell counts detected in the patients before and after surgery and following chemotherapy and those pa -tients with different TNM staging and molecular typing.Results There were statistical differences in CD4+cell counts and TNM stag-ing between the patients with malignant and benign tumors(P<0.05;P<0.05).There were also statistical differences in CD8+cell counts,when comparisons were made between the patients with malignant and benign tumors, before and after surgery and following chemotherapy,and between different age stages(P<0.05;P<0.05).After chemotherapy, there were statistical differences between different TNM stages(P=0.001)and molecular types(P =0.011).Statistical differences could also be seen in B cells between malignant and benign tumors,between before and after chemotherapy as well as between different age stages(P<0.05;P<0.05;P<0.05).After surgery,statistical differences could also be noted between different TNM stages(P =0.026)and molecular types(P =0.022).CD8+and B cells might be prognostic factors, however, the levels of CD8+and B cells were not necessarily independent predictors of survival after breast cancer treatment.Conclusion The levels of B cells, CD4+and CD8+in peripheral blood have a certain value for the diagnosis and prognosis of breast cancer patients,for this reason,it is worth further research and may promise fu-ture clinical application.

Objective · To prepare the liposomal pemetrexed and investigate its effects on MCF-7 breast cancer cells in vitro and nude mice bearing MCF-7 xenograft tumors. Methods · Liposomal pemetrexed was prepared by film dispersion method. Inhibition of MCF-7 breast cancer cell lines was evaluated by CCK-8 method, and anti-tumor effects were investigated on Balb/c nude mice bearing MCF-7 xenograft tumors. Results · Liposomal pemetrexed inhibited the growth of MCF-7 cells. When the concentrations of pemetrexed were 0.20, 0.40 and 10.00 μg/mL, the cell viability in experiment group (liposomal pemetrexed) was significantly lower than that in control group (pemetrexed of same concentration gradient), with P values of 0.013, 0.035 and 0.041, respectively. Compared with blank group (same volume of PBS), the volumes and weights of tumors of nude mice in experiment group(liposomal pemetrexed) and control group (same volume of pemetrexed) were significantly lower, and the volume and weight of tumor in experiment group were also significantly lower than those in control group (P=0.000). Conclusion · Compared to bulk drug of pemetrexed, liposomal pemetrexed can inhibit the growth of MCF-7 breast cancer cells and the Balb/c nude mice bearing MCF-7 xenograft tumors.

OBJECTIVETo study the influence of micrometastasis in lymph node on staging and prognosis of non-small-cell lung cancer (NSCLC).

METHODSIn 39 NSCLC patients, micrometastasis in pathologically negative lymph nodes were tested through immunohistochemical cytokeratin (CK) analysis and the relationship between CK(+) and staging, survival were analyzed.

RESULTSIn these 39 patients, the survival of CK(+) and CK(-) patients were 32 months and 48 months respectively (P = 0.0178). Multivariate analysis of Cox regression model showed: clinical stage (P = 0.0288) and relapse or metastasis (P = 0.0053) affected the prognosis while micrometastasis in lymphnodes (P = 0.7740) did not.

CONCLUSIONThe detection of micrometastasis in the lymphnodes may serve as a supplement to the present staging system for lung cancer. Even though the prognosis of patients with micrometastasis being poorer than those without, micrometastasis in the lymph nodes should not be regarded as an independent prognostic factor.

Adult ; Aged ; Carcinoma, Non-Small-Cell Lung ; diagnosis ; metabolism ; secondary ; Female ; Humans ; Keratins ; metabolism ; Lung Neoplasms ; diagnosis ; metabolism ; pathology ; Lymph Nodes ; pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis